We compared the efficiency of retroviral vector (N2)-mediated transfer of the bacterial neomycin resistance gene (NeoR) into adult and fetal hematopoietic progenitors of sheep and humans by assessing their ability to form colonies in the presence of lethal doses of the neomycin analogue G4t8 in vitro. Fetal cells from both sheep and humans exhibited a higher degree of NeoR transfer than adult cells. The overall level of NeoR expression was significantly higher for sheep than human cells. The transfer/expression of NeoR into adult human bone marrow hematopoietic progenitors was not affected by the pres-ENE THERAPY INVOLVING the transfer of a G functioning exogenous gene into the appropriate somatic cells (eg, hematopoietic cells) of an organism offers a precise means of treating a genetic
The insertion of genes into hematopoietic cells has been greatly facilitated by the use of retroviral Genes can be transferred with high efficiency into mouse hematopoietic and rabbit endothelial cells,13 and, with lesser efficiency, into dogl4 and human6*'*'' hematopoietic cells. Postnatal gene transfer studies in dogsI4 and monkeys' using a bone marrow transplantation/retroviral gene transfer protocol demonstrated the feasibility of gene transfer and expression in large animals. However, the transfer/expression occurred at very low effi~iency.~.'~ Using an in utero gene transfer protocol involving the retroviral-mediated transfer of the bacterial neomycin resistance gene (NeoR) into hematopoietic cells obtained from the circulation of fetal sheep, we recently reported the long term expression of the NeoR gene in sheep at significantly higher efficiency than has been observed in other large animal models.I6 In the present study, we explored the possibility that the relatively higher level of NeoR transfer/ expression found in sheep using the in utero gene transfer protocol correlates with a greater efficiency of retroviralmediated NeoR transfer into fetal than into adult hematopoietic progenitors. The results presented here demonstrate that fetal hematopoietic progenitors from both sheep and humans exhibit significantly greater efficiency of retroviral-mediated NeoR transfer than adult hematopoietic progenitors, and the efficiency of NeoR transfer was higher in sheep than in human cells.
MATERIALS AND METHODS
Bone marrow was aspirated from the posterior iliac crest, and placed into heparinized (preservative-free) Iscove's Modified Dulbecco's Medium (IMDM). The samples were centrifuged at 600 x g for 15 minutes, and the buffy coat cells were separated, washed in IMDM, 2% fetal calf serum (FCS) twice and resuspended in IMDM, 10% FCS. Bone marrow was obtained from normal, healthy adult volunteer donors after obtaining informed consent. Bone marrow mononuclear cells (BMC) were isolated by Ficoll-Hypaque densitygradient centrifugation (1.077 sp. gravity). When required, BMC were depleted of monocytes (MO) by adherence to plastic surfaces, and of T cells by rosetting with sheep red blood cells." Preparation of sheep and human fetal liver cells. Livers were obtained from sheep fetuses delivered by Caesarian section at 90 to 100 days of gestation. These fetuses also served as the source of fetal sheep bone marrow cells. Fetal livers were obtained from aborted human fetuses (17 to 23 weeks of gestation). After women had independently requested and scheduled pregnancy termination, informed consent was obtained for the use of the tissue for research. In order to prepare fetal liver cells, slices of liver were washed (three times in heparinized IMDM, 10% FCS) and passed through a sterile wet stainless steel screen mesh (0.2 mm pore size) under constant stream of IMDM, 10% FCS. Single cell suspension was obtained by passage of the mixture through a 25-gauge needle. The mixture was allowed to stand at room temperature for 5 minutes and the top 2/3 of the cell suspension was removed, pelleted by centrifugation (600 x g, 10 minutes), and in the case of fetal sheep liver, resuspended in IMDM, 10% FCS and kept at 4OC until used. Human fetal liver hematopoietic cells were further processed by isolation on FicollHypaque density gradient prior to use.
Single cell suspensions of fetal sheep bone marrow were prepared by flushing femurs obtained from 90-to 100-day-old fetuses (see above) with heparinized IMDM, 10% FCS. The cell suspension was passed through a 25-gauge needle, washed twice, and resuspended in IMDM, 10% FCS.
Gene transfer protocol. The N2 vector, a Moloney murine leukemia virus-based vector with the viral coding sequences removed and the NeoR gene from the bacterial Tn5 transposon inserted into it, 366 EKHTERAE ET AL was used in these studies. The construction and packaging of this vector in PA317 cells is described in detail el~ewhere.'~,'~ The virus-containing medium (VCM) had a titer for NeoR of 1.6 x 106/mL on NIH3T3 cells and was minimally (less than 10%) contaminated with amphotropic helper. The following procedure was used to transduce the hematopoietic cells of sheep and humans. VCM was diluted 1:3 for sheep experiments and 1 5 for human experiments with fresh IMDM, 10% FCS, and polybrene was added to a final concentration of 8 ug/mL. Sheep adult and fetal cells were added at a concentration of 2.5 x lo5 cells/mL to 40 mL of diluted VCM/polybrene mixture, mixed thoroughly and incubated overnight (12 to 14 hours) at 37OC (5% CO, in humidified air) with frequent gentle agitation. The cells were then pelleted, washed twice, and resuspended in IMDM, 10% FCS. Human adult and fetal cells were added at the same concentration to diluted VCM/polybrene mixture in the presence or absence of 100 ng/mL recombinant human interleukin-3 (IL-3, Genetics Institute, Cambridge, MA) and 400 ng/mL recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF; Genetics Institute) (with adult bone marrow cells) or 2.5 ng/mL IL-3 and 50 ng/mL GM-CSF (with fetal liver cells), mixed gently about every hour while incubating for 20 to 24 hours at 37OC (5% CO, in humidified air). The cells were then pelleted, washed and resuspended in IMDM, 10% FCS.
Hematopoietic progenitors assays. The presence/activity of the NeoR gene in hematopoietic progenitors was assayed by testing adult and fetal hematopoietic cells for resistance to the neomycin-like antibiotic G418 (GIBCO, Grand Island, NY). Aliquots of adult sheep bone marrow cells (2 to 8 x 105/mL), sheep fetal marrow and liver cells (0.4 to 2 x 105/mL), human bone marrow cells (2 to 4 x 105/mL), human bone marrow cells depleted of MO and T cells (0.5 to 4 x 105/mL), and human fetal liver cells (4 x 105/mL) were cultured in plasma clot (colony forming unit-erythroid [CFU-E], burst-forming unit-erythroid [BFU-E]) or methylcellulose (CFUMix, CFU-C, BFU-E) as described.'"" The cells were cultured in the presence or absence of different concentrations of G418 (0.1 to 2 mg/mL), erythropoietin (0.4 IU/mL with sheep cells, 0.5 IU/mL with human cells), and a preparation of phytohemagglutininstimulated leukocyte conditioned medium (PHA-LCM) (5% vol/ vol) derived from sheep or human blood leukocytes. The plates were incubated at 37OC in a humidified atmosphere of 5% CO, in air for 4 (sheep CFU-E), 7 (human CFU-E), 9 to 12 (sheep CFU-Mix, CFU-GM, BFU-E), and 14 (human CFU-Mix, CFU-GM, BFU-E) days. Colonies in plasma clot were examined after transfer, fixing, and staining on glass slides; colonies in methylcellulose cultures were enumerated in situ.
RESULTS
In a series of studies, the effect of different concentrations (0.1, 0.4, 1.2, 1.5, and 2.0 mg/mL) of G418 on colony formation by normal (untransduced) fetal and adult sheep and human hematopoietic progenitors in vitro was determined. Figure 1 shows that the formation of colonies by normal sheep and human fetal and adult CFU-Mix, CFU-GM, and BFU-E was inhibited by G418 in a dose-dependent fashion. Some colonies were detectable at 1.5 mg/mL G418. At 2 mg/mL, however, no colonies were observed with human cells, and sheep cells produced very few colonies. In subsequent experiments, therefore, a concentration of 2 mg/mL G418 was used.
Results presented in Table 1 demonstrate the relative efficiency of NeoR transfer into sheep hematopoietic progenitors in vitro. When compared with untransduced cells, colony growth by vector-treated cells was normal in number, morphology, and size in the absence of G418 selection. At 2 mg/mL of G418, a small number of colonies were observed in cultures of untreated cells. By contrast, significant numbers of colonies produced by all four progenitor classes assayed were detected in cultures of transduced cells in the presence of 2 mg/mL G418 (Table 1) . For a majority of these progenitors, those derived from fetal sheep exhibited greater efficiency of NeoR transfer than adult cells. However, the differences between fetal and adult sheep erythroid progenitors were not as pronounced. Vector-exposed fetal BFU-E were only moderately more resistant to G418 than adult sheep marrow BFU-E, and there was essentially no difference in the numbers of G418-resistant CFU-E (Table   The results of studies with human hematopoietic cells are presented in Table 2 . As with the sheep, N2-treated human cells cultured in the absence of G418 produced hematopoietic colonies that were normal in number, size, and morphology, indicating that the gene transfer protocol used in these studies did not adversely affect these progenitors. Unlike the sheep, however, we did not detect any G418-resistant CFUMix in cultures of infected adult human bone marrow cells (Table 2) . However, human fetal liver cells exposed to the N2 vector exhibited about 5% G418-resistant CFU-Mix-1). derived colonies in vitro. Human fetal liver cells also produced higher percentages of G418-resistant CFU-GM colonies than adult human marrow cells, and unlike the sheep, infected human fetal liver cells exhibited higher percentages of G418-resistant BFU-E and CFU-E than human adult marrow ( Table 2) . The results presented in Table 3 demonstrate that transduction in the presence of IL-3 and GM-CSF improved the efficiency of NeoR transfer into both human adult and fetal hematopoietic progenitors. However, the level of improvement varied among the different progenitor classes, which may reflect the differential effect of these growth factors on these progenitors.
To determine whether the efficiency of transduction can be improved by increasing the number of progenitors exposed to VCM, the efficiency of transduction of whole bone marrow cells was compared with bone marrow cells depleted of MO and T cells. BMC (5 x lo6) or BMC-MO-T were exposed to VCM (see Materials and Methods) and then cultured in methylcellulose and plasma clot in the presence or absence of 2 mg/mL G418. Table 4 shows that there was no improvement in the efficiency of NeoR transfer when T-and MOdepleted BMC was used, despite the increased progenitor incidence in culture.
DISCUSSION
The results presented here demonstrate the greater efficiency of retroviral-mediated NeoR transfer into fetal hematopoietic progenitors than into adult progenitors in vitro. This was apparent from the greater percentages of fetal progenitors of nearly all classes that exhibited resistance to G418 after exposure to the retroviral vector. This difference was more pronounced for human than for sheep cells. However, the efficiency of NeoR transfer was considerably higher in sheep than in human cells. The average overall percentage of G418-resistant progenitors for adult sheep was 12.20 f 1.90%, as compared with 0.85 f 0.33% for adult human bone marrow progenitors. Similarly, 21.22 f 2.27% of fetal sheep liver (and 19.49 f 1.54% of fetal sheep marrow) hematopoietic progenitors exhibited G418-resistance, while 5.33 0.36% of human fetal progenitors survived exposure to 2 mg/mL G418. It is unlikely that these differences in the efficiency of NeoR transfer between sheep and human cells were associated with the different ratios of viral particles to target cells used in these studies. Although the ratio of viral particles to target cells varied somewhat between the sheep and human experiments (VCM was diluted 1:3 and 1 5 for sheep and human cells, respectively), 
368
EKHTERAE ET AL when adult human bone marrow cells were incubated with undiluted VCM, the percentages of G418-resistant progenitors (CFU-Mix, 0%; CFU-GM, 1.6%; BFU-E, 2%; CFU-E, 1%) were not significantly different from those obtained with the diluted preparation of the N2 vector (CFU-Mix, 0%;
exposure of these progenitors to hematopoietic growth factors GM-CSF and IL-3 improved the efficiency of NeoR transfer/expression (Table 3) , sheep progenitors continued to express the gene at significantly higher levels. Successful postnatal in vivo gene transfer into hematopoietic cells with the expression of the exogenous gene has been achieved in the m o u~e~-~* '
but not in primates' or dogs.14 Both the relative ease with which sheep hematopoietic progenitors appear to become transduced with the N2 vector and the higher efficiency of NeoR transfer/expression into fetal sheep progenitors correlates with the relatively efficient transfer/ expression of NeoR gene in sheep using the in utero gene transfer protocol.'6 These findings combined with other fetal characteristics such as the availability of bone marrow spaces (obviating the need for cytoablative therapy), the absence of immediate demand upon the newly engrafted stem cells (hematopoiesis in the fetus is generally maintained by CFU-GM, 1.6%; BFU-E, 1%; CFU-E, 0.8%). Although hepatic/splenic activity), and the generally favorable growth environment of the fetus, were likely contributing factors to the success of the in utero gene transfer protocol.16 In our hands, the more primitive progenitor CFU-Mix from adult human bone marrow did not express NeoR activity in vitro. However, adult sheep marrow CFU-Mix exhibited relatively high levels of G418 resistance. A significant percentage of human fetal liver CFU-Mix also survived the addition of G418 to culture. It is possible that the increased numbers of target CFU-Mix (and of other progenitors) assayed in fetal preparations contributed to the greater efficiency of NeoR transfer. However, increasing the concentration of hematopoietic progenitors, including CFU-Mix, in preparations of adult human bone marrow by accessory cell depletions to levels exceeding those present in fetal liver cells failed to influence the transfer/expression of NeoR into adult human CFU-Mix (Table 4) . Whether or not differences in the proliferative state of the fetal and adult CFU-Mix play a role in this process is not known. The transfer of the exogenous gene to the more primitive hematopoietic stem cells is important for the successful long term expression of the gene in vivo.'-z' The long term expression of the NeoR gene observed in sheep after in utero gene transfer suggests that Three separate experiments, each involving a separate donor, were conducted. Each cell preparation was cultured before (2 to 4 x 10' cells/mL) and after (0.5 to 4 x lo5 cells/mL) depletion of adherent monocyte/macrophages (MO) and T lymphocytes. Transduction was carried out in the absence of IL-3 and GM-CSF.
'Each value represents the total number of colonies assessed in the three separate experiments. Values in parentheses indicate percent resistance colonies.
the transduction of at least some multipotent stem cells had occurred. '6 Except for diseases such as adenosine deaminase (ADA) deficiency, where a natural pressure for the growth of the treated cells may exist,' most postnatal gene therapy attempts will likely require cytoablation of the patient's marrow, with all the risks that this procedure involves. In addition, there are a number of inherited metabolic diseases (eg, Lesch-Nyhan, Tay Sachs) that can produce irreversible damage to the fetus prior to birth. The greater efficiency of gene transfer into fetal hematopoietic progenitors, and the feasibility of the in utero gene transfer protocol in most large animal species, suggest that gene therapy in utero may be a reasonable therapeutic option in some of these disorders.
